CLDN18.2 inhibitor obtained via Ganymed deal shows survival benefit in first of two Phase III trials

Plus data from Zymeworks, Leap and Acepodia

Partners believe asset can address conditions for which other ADCs haven’t been approved

Shares of G1 Therapeutics Inc. (NASDAQ:GTHX) rose 20% to $37.15 in after-hours trading after FDA approved Cosela trilaciclib to decrease bone marrow suppression caused by chemotherapy in adults

Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract and gastroesophageal cancers, respectively. In an oral

Novartis’ PD-1 misses in melanoma comboNovartis AG (NYSE:NVS; SIX:NOVN) said spartalizumab missed the primary endpoint of the Phase III COMBI-i trial in patients with untreated, unresectable

Incyte’s Pemazyre pemigatinib approved for cholangiocarcinoma; Everest gains first approval via Singapore